Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Fujifilm Diosynth Biotechnologies Commissions New Cell Banking Facility

Published: Monday, April 22, 2013
Last Updated: Monday, April 22, 2013
Bookmark and Share
Fujifilm Diosynth Biotechnologies has commissioned on time its new mammalian cGMP Cell Banking Facility (CBF) at its Billingham, UK site.

The new CBF is available to the company’s customers either as part of a larger development and manufacturing programme, or as a stand-alone service. It forms the second stage of a major expansion of the company’s mammalian cell culture capabilities at the site, following installation last year of new process development and scale-up capabilities. The asset will support delivery of manufacturing programmes for both Fujifilm Diosynth Biotechnologies’ Billingham UK, and Research Triangle Park, North Carolina, USA facilities.

The next stage of the company’s expansion will be the commissioning of a new cGMP manufacturing facility, also in Billingham, which is well under construction, and due on-line in early Q4 2013. This manufacturing facility, which will primarily utilise single-use technologies, has been designed with input from regulatory authorities and key customers, to offer high flexibility for meeting customers’ needs and setting new standards. It will initially offer 200L and 1000L single-use bioreactors, with 2000L bioreactors already planned for 2014.

Steve Bagshaw, Managing Director, Fujifilm Diosynth Biotechnologies UK, said “I am delighted that we have commissioned the Cell Bank Facility within a year of its commencement, and have already started work on our first customer programme. This is the next step in our strategy to grow our services in the CDMO field, becoming a world-class player across both microbial and mammalian cell culture platforms, offering a full life cycle support for our customers”.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Fujifilm Diosynth Biotechnologies’ Opens New Manufacturing Facility
Fujifilm Diosynth Biotechnologies today formally opened its new mammalian cell culture cGMP manufacturing facility.
Wednesday, October 02, 2013
Scientific News
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Speeding Up the Process of Making Vaccines
System uses a freeze-dry concept to develop "just-add-water" solution.
Surprising Trait Found in Anti-HIV Antibodies
Scientists at The Scripps Research Institute (TSRI) have new weapons in the fight against HIV.
New Method Identifies Up to Twice as Many Proteins and Peptides
An international team of researchers developed a method that identifies up to twice as many proteins and peptides in mass spectrometry data than conventional approaches.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Genetically Engineering Algae to Kill Cancer Cells
New interdisciplinary research has revealed the frontline role tiny algae could play in the battle against cancer, through the innovative use of nanotechnology.
Novel Stem Cell Line Avoids Risk of Introducing Transplanted Tumors
Progenitor cells might eventually be used to repair or rebuild damaged or destroyed organs.
Single Vaccine for Chikungunya, Related Viruses May be Possible
What if a single vaccine could protect people from infection by many different viruses? That concept is a step closer to reality.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos